Drug Profile
Aclidinium bromide - Covis Pharma
Alternative Names: Aclinidinium; Bretaris Genuair; Eklira Genuair; KRP-AB1102; LAS-34273; Tudorza Pressair; TudorzaGenuairLatest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator Almirall-Prodesfarma
- Developer Allergan; Almirall S.A.; AstraZeneca; Covis Pharma; Daewoong Pharmaceutical; Forest Laboratories; Kyorin Pharmaceutical
- Class Antiasthmatics; Antibronchitics; Bronchodilators; Quinuclidines; Small molecules; Tropanes
- Mechanism of Action Muscarinic M3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Chronic obstructive pulmonary disease
- No development reported Asthma
Most Recent Events
- 26 Nov 2021 AstraZeneca completes a phase-I trials in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation) (NCT03276052)
- 01 Nov 2021 Covis Pharma acquires aclidinium bromide from AstraZeneca
- 14 Oct 2021 Phase-I clinical trials in Chronic obstructive pulmonary disease (In volunteers) in China (Inhalation) (NCT03276052)